Clinical trials: C. Difficile
Clostridium Difficile Infection
Clostridium Difficile Vaccine Efficacy Trial
The Clover trial is evaluating an investigational vaccine that may help to prevent Clostridium difficile infection. Participants in the study are adults 50 years of age and older, who are at risk of developing Clostridium…
- Trial name
- Clover (NCT03090191)
- Testing
- Clostridium difficile vaccine
- Where
- 426 sites in United States, Argentina and 21 more
- Volunteers
- 17,535 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile Associated Disease
Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age
This study will investigate a Clostridium difficile vaccine in healthy adults 65 to 85 years of age, who will each receive 3 doses of vaccine.
- Trial name
- NCT03579459
- Testing
- Clostridium difficile vaccine
- Where
- 24 sites in United States
- Volunteers
- 1,317 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile Infection, Multi Drug Resistant Organisms
Establishment of the Human Intestinal and Salivary Microbiota Biobank - Gastrointestinal Diseases
This is a prospective, clinical, multicentre study aimed to collect biological samples and study microbiota from subjects with Clostridium Difficile (CDI), subjects affected by Multi Drug Resistant Organisms (MDRO) infection…
- Conditions
- Clostridium Difficile Infection, Multi Drug Resistant Organisms, Chronic Inflammatory Bowel Disease, Irritable Bowel Syndrome
- Trial name
- BIOMIS-Gastr (NCT04698148)
- Testing
- Biological sample collection, Questionnaire, Medical examination
- Where
- 3 sites in Italy
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Clostridium Difficile Infection
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
The aim of this study was to evaluate the efficacy of the Clostridium difficile vaccine to prevent primary symptomatic C. difficile infection (CDI) in participants at risk for CDI where there is a substantial unmet medical need.
- Trial name
- NCT01887912
- Testing
- C. difficile Toxoid Vaccine
- Where
- 335 sites in United States, Australia and 24 more
- Volunteers
- 9,302 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Urinary Tract Infections, Infectious Diarrhea
Creation of an E-toileting Log Through Classification of the Physical Properties of Stool and Urine Using TrueLoo™
The purpose of this study is to assess the feasibility of TrueLoo™, an Internet-connected smart toilet seat, in accurately monitoring and logging bowel movements and urinations of residents in senior living facilities across…
- Conditions
- Urinary Tract Infections, Infectious Diarrhea, Clostridium Difficile Infection, Gastrointestinal Disease
- Trial name
- NCT05008640
- Testing
- TrueLoo™
- Where
- 6 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Toi Labs, Inc.
Clostridium Difficile Associated Disease
A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years
This study will investigate a Clostridium difficile vaccine in healthy adults aged 65-85 years. Each subject will initially receive 3 doses of vaccine on 1 of 2 vaccination schedules.
- Trial name
- NCT02561195
- Testing
- Clostridium difficile Vaccine
- Where
- 17 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diarrhea, Clostridium Difficile
Probiotics in the Prevention of Antibiotic Induced Diarrhea and Clostridium Difficile Associated Diarrhea.
The objective of this study is to determine the efficacy of probiotics containing 25Bn (billion) CFU (colony-forming unit) of Lactobacillus rhamnosus, Sacchromyces boulardii and Bifidobacterium breve in the prevention of…
- Trial name
- NCT03647995
- Testing
- Probiolife by Green Made (Pharma M)
- Where
- Lebanon
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Yara El Helou
Clostridium Difficile
Effectiveness of Isolating Clostridium Difficile Asymptomatic Carriers on the Incidence of Infections
Background: There is an urgent need to develop new strategies to prevent Clostridium difficile infections (CDI). A recent study suggests that a novel infection control bundle (IC bundle) can lead to a significant decrease in the…
- Trial name
- EFFICACI (NCT03223415)
- Testing
- Detection and isolation of C. difficile carriers
- Where
- 5 sites in Canada
- Volunteers
- 4,138 people, healthy volunteers welcome
- Sponsor
- Yves Longtin
Clostridium Difficile, Inflammatory Bowel Diseases
Seroprevalence of Anti-bodies Against Clostridium Difficile Toxins and Prevalence of Asymptomatic Carriage of Clostridium Difficile in IBD Patients.
The objective of this study to evaluate the seroprevalence of anti-bodies against C. difficile toxins A and B and the asymptomatic carriage of C.
- Trial name
- NCT03889808
- Testing
- Determination of serum anti-toxin Abs for C. difficile
- Where
- Spain
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Hospital Universitari de Bellvitge
Clostridium Difficile
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
This study will investigate a clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine.
- Trial name
- NCT02052726
- Testing
- C. difficile vaccine with adjuvant
- Where
- 10 sites in United States, Canada
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile Infection, Diarrhea
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
This study will further evaluate the ACAM-CDIFF™ vaccine in a population of middle-aged to elderly individuals at risk of exposure to Clostridium difficile because of impending hospitalization or residence in a care facility.
- Trial name
- NCT01230957
- Testing
- Clostridium difficile toxoids A and B (Low-dose with adjuvant), Clostridium difficile toxoids A and B (Low-dose without adjuvant), Clostridium difficile toxoids A and B (high-dose with adjuvant)
- Where
- 30 sites in United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Clostridium Difficile Infection
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan
The aim of the study is to evaluate a candidate C. difficile Toxoid Vaccine in the Japanese population. Primary objectives: To describe the safety profile of all subjects who receive at least 1 injection To describe the…
- Trial name
- NCT01896830
- Testing
- Clostridium difficile Toxoid Vaccine, 0.9% normal saline
- Where
- Japan
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Clostridium Difficile Associated Disease
Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults
The first-in-Japanese study B5091010 has been designed to evaluate the safety, tolerability, and immunogenicity of 2 antigen dose levels of C difficile vaccine when administered as one of two 3-dose regimens to healthy Japanese…
- Trial name
- NCT02725437
- Testing
- Clostridium difficile Vaccine
- Where
- 2 sites in Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Pfizer
Clostridium Difficile, Clostridium Difficile Infection
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
To assess the association between Clostridium difficile (CD) toxins' serum levels and the grade of Clostridium difficile infection (CDI) severity/failure to CDI treatment and rate of recurrence.
- Trial name
- NCT03586206
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Roma Tre University
Clostridium Difficile Colitis
Phase I Trial of a Single Dose of CRS3123
Double-blind, randomized, placebo-controlled Phase I Trial to determine the safety and pharmokinetics of a single dose of CRS3123 in healthy adult volunteers.
- Trial name
- NCT01551004
- Testing
- CRS3123
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridium Difficile Infection
Oral Vaccination Against Clostridium Difficile Infection
This clinical study is conducted to assess the safety and immunogenicity of a Clostridium difficile vaccine (CDVAX) in healthy adult volunteers.
- Trial name
- CDVAX (NCT02991417)
- Testing
- CDVAX
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Simon M. Cutting
Clostridium Difficile
Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study
Phase 2, randomized, observer-blind, placebo-controlled, multi-centric study including 4 parallel study groups. 500 Subjects (thereof, 250 aged 50 - 64 years and 250 aged 65 years and older) will be randomized in a (3:3:3:1)…
- Trial name
- NCT02316470
- Testing
- VLA84
- Where
- 10 sites in United States, Germany
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Crohn's Disease, Ulcerative Colitis
Host Immune Response to Clostridium Difficile Infection in Inflammatory Bowel Disease Patients
The inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn's disease (CD) are chronic conditions affecting approximately 1.4 million Americans.
- Conditions
- Crohn's Disease, Ulcerative Colitis, Clostridium Difficile, Inflammatory Bowel Disease
- Trial name
- NCT01813500
- Testing
- Blood and stool sample
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Boston Medical Center
Clostridium Difficile Infection
Pathogenic Mechanisms in C Diff Infection and Colitis
The purpose of this study is to learn more about infection by Clostridium difficile (also known as C. difficile). C. difficile is a common bacterium (a germ that may cause disease) that can live in the human gut.
- Trial name
- NCT01930032
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Beth Israel Deaconess Medical Center
Clostridium Difficile Associated Disease
A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.
This study will investigate a Clostridium difficile vaccine in healthy adults aged 50 to 85 years, who will each receive 3 doses of vaccine.
- Trial name
- NCT02117570
- Testing
- Clostridium difficile vaccine
- Where
- 12 sites in United States
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Pfizer